Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Company Ltd
(OP:
ESALF
)
56.84
UNCHANGED
Streaming Delayed Price
Updated: 1:04 PM EDT, Sep 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
56.84
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
56.84
Today's Range
56.84 - 56.84
52wk Range
52.42 - 76.96
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
September 22, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC:
Via
Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
August 25, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck...
Via
Benzinga
Performance
YTD
-6.05%
-6.05%
1 Month
-10.85%
-10.85%
3 Month
-15.59%
-15.59%
6 Month
+3.16%
+3.16%
1 Year
-9.49%
-9.49%
More News
Read More
Current Analysis: Eisai Co Ltd (ESAIY)
July 16, 2023
Via
Talk Markets
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
Via
Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
Via
Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
Via
Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
Via
Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
Via
Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
Via
Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Via
Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
Via
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
Via
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Via
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Via
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Via
Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Via
Benzinga
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Via
InvestorPlace
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
January 06, 2023
Via
Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
Via
Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Via
Benzinga
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
Via
Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
Via
Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
Via
Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Via
Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.